HALOG-E
Clinical safety rating: caution
Comprehensive clinical and safety monograph for HALOG-E (HALOG-E).
HALOG-E (halcinonide) is a corticosteroid that binds to glucocorticoid receptors, inducing the synthesis of lipocortin, which inhibits phospholipase A2, thereby reducing arachidonic acid release and subsequent production of prostaglandins and leukotrienes. This results in anti-inflammatory, antipruritic, and vasoconstrictive effects.
| Metabolism | Hepatic metabolism via CYP3A4; topical absorption can lead to systemic metabolism. |
| Excretion | Renal (primarily as conjugates, 60-80%), fecal (15-30%), less than 5% unchanged in urine. Biliary excretion contributes to fecal elimination. |
| Half-life | Terminal elimination half-life 8-14 hours, prolonged in hepatic impairment; clinical effect persists 24-36 hours due to tissue retention. |
| Protein binding | Approximately 99% bound, primarily to corticosteroid-binding globulin (CBG) and albumin. |
| Volume of Distribution | Vd approximately 0.3-0.5 L/kg, indicating extensive tissue distribution and high affinity for glucocorticoid receptors. |
| Bioavailability | Topical: percutaneous absorption varies with skin condition; approximately 1-7% in intact skin, increases up to 36% in inflamed or abraded skin. Not administered orally or parenterally; thus, bioavailability by other routes is not applicable. |
| Onset of Action | Topical: onset of vasoconstriction within 1-2 hours; therapeutic effect on inflammation and pruritus within 3-5 days of regular application. |
| Duration of Action | Topical: duration of vasoconstriction 12-18 hours per application, with therapeutic benefit sustained for 1-2 weeks after cessation due to reservoir effect in stratum corneum. |
Apply a thin film to affected area twice daily. Initial therapy may be occlusive. Max 60 g/week.
| Dosage form | CREAM |
| Renal impairment | No adjustment required. |
| Liver impairment | No adjustment required. |
| Pediatric use | Not recommended for use in pediatric patients due to higher skin surface-to-body weight ratio and increased systemic absorption. |
| Geriatric use | Use with caution; apply sparingly to limited areas. Avoid prolonged use, occlusive dressings, and use over large body surface areas. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for HALOG-E (HALOG-E).
| Breastfeeding | Excreted in breast milk; M/P ratio unknown. Potential for adrenal suppression in breastfeeding infant. Use caution; avoid high doses or prolonged use while nursing. |
| Teratogenic Risk | FDA Pregnancy Category C. In first trimester, risk of cleft palate and cardiac malformations based on animal studies; human data limited. Second and third trimesters: risk of fetal adrenal suppression, intrauterine growth restriction, and preterm labor. Use only if benefit outweighs risk. |
| Fetal Monitoring |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to halcinonide or any component of the formulation","Untreated bacterial, fungal, or viral skin infections"]
| Precautions | ["Systemic absorption may cause reversible HPA axis suppression, especially in children and with prolonged use on large areas.","Avoid use on face, groin, or axillae due to increased risk of atrophy.","Topical corticosteroids may increase risk of skin infections and mask signs of infection.","Use with caution in patients with hepatic impairment due to altered metabolism."] |
Loading safety data…
| Monitor fetal growth via ultrasound for signs of IUGR. Assess for maternal hypertension, hyperglycemia, and signs of infection. Monitor infant for adrenal suppression if exposed in utero. |
| Fertility Effects | May impair fertility in animal studies (ovarian and spermatogenesis disruption). Human data insufficient; potential for reversible menstrual irregularities. |